Market Overview

Alexion's Valuation Could Be Getting Pummeled Unnecessarily

Share:

Leerink said in a note Tuesday that the delay in a 10-Q filing has pushed Alexion Pharmaceuticals, Inc's. (NASDAQ: ALXN) valuation to ridiculous levels. The firm noted that the stock has continued its underperformance relative to its large-cap high growth peers such as Regeneron and Vertex, missing out on the post-election biotech rally.

Over a 10-day period, analyst Geoffrey Porges noted that a 30 percent valuation gap has emerged between Alexion's stock and its peers. The pounding, according to the analyst, has taken absolute valuation towards worst-case downside scenarios, which could materialize only if there is failure of pipeline indications and of any future Soliris label expansions.

Leerink models valuation of $100 for the current Soliris label, Strensiq and Kanuma, assuming no improvement in operating margins. However, if operating margins improve, the firm sees valuation at $125.

The firm believes the current stock pullback presents a unique opportunity for investors, and potentially trade buyers, to secure a long duration, high potential, high margin biopharmaceutical franchise. Once the uncertainty surrounding the internal investigations delaying the 10-Q filing is resolved, which is likely to occur by the end of the month, the firm believes the stock can recover to around $150.

As such, the firm has an Outperform rating and $211 price target on shares.

Latest Ratings for ALXN

DateFirmActionFromTo
Nov 2020BernsteinInitiates Coverage OnMarket Perform
Oct 2020Morgan StanleyMaintainsEqual-Weight
Oct 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

 

Related Articles (ALXN)

View Comments and Join the Discussion!

Posted-In: Geoffrey Porges LeerinkAnalyst Color Biotech Analyst Ratings General

Latest Ratings

StockFirmActionPT
CAMTStifelInitiates Coverage On19.0
ELMDNorthland Capital MarketsInitiates Coverage On15.0
DKNGUBSInitiates Coverage On52.0
DIODTruist SecuritiesInitiates Coverage On84.0
TGTArgus ResearchUpgrades205.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com